{ "description": "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial", "_filename": "example/Evidence-179635.json", "package_name": "hl7.fhir.uv.ebm", "statistic": [ { "quantity": { "value": 1.59 }, "sampleSize": { "numberOfParticipants": 68 }, "description": "18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)", "statisticType": { "coding": [ { "code": "STATO:0000245", "system": "https://fevir.net/sevco", "display": "Risk Ratio" } ] }, "numberAffected": 30, "attributeEstimate": [ { "type": { "coding": [ { "code": "STATO:0000700", "system": "https://fevir.net/sevco", "display": "p-value" } ] }, "quantity": { "value": 0.01, "comparator": "<" }, "description": "p < 0.01" } ] } ], "date": null, "meta": { "profile": [ "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence" ], "versionId": "7", "lastUpdated": "2024-12-13T21:07:33.593Z" }, "publisher": "Computable Publishing LLC", "name": "ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial", "useContext": [ { "code": { "code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication" }, "valueCodeableConcept": { "coding": [ { "code": "ComparativeParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ComparativeParticipantFlowEvidence" } ] } } ], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "type": null, "experimental": null, "resourceType": "Evidence", "variableDefinition": [ { "description": "Participants in the opioid detoxification trial", "variableRole": "population" }, { "description": "GroupAssignment: Lofexidine vs. Placebo", "variableRole": "exposure", "comparatorCategory": "false" }, { "observed": { "type": "EvidenceVariable", "display": "PartiicipantFlowMeasure: Dropout due to stopping intervention", "reference": "EvidenceVariable/179636" }, "description": "Dropout due to stopping intervention", "variableRole": "outcome" } ], "title": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial", "package_version": "1.0.0-ballot2", "author": [ { "name": "Brian S. Alper" } ], "extension": [ { "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to", "extension": [ { "url": "type", "valueCode": "cite-as" }, { "url": "targetMarkdown", "valueMarkdown": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635#json." } ] }, { "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to", "extension": [ { "url": "type", "valueCode": "derived-from" }, { "url": "targetReference", "valueReference": { "type": "Citation", "display": "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal", "reference": "Citation/179637" } } ] } ], "status": "active", "id": "22ea3237-2e94-4f6c-9a8a-634dcea68771", "kind": null, "url": "https://fevir.net/resources/Evidence/179635", "identifier": [ { "type": { "text": "FEvIR Object Identifier", "coding": [ { "code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID" } ] }, "value": "https://fevir.net/FOI/179635", "system": "urn:ietf:rfc:3986", "assigner": { "display": "Computable Publishing LLC" } } ], "version": null, "contact": [ { "telecom": [ { "value": "support@computablepublishing.com", "system": "email" } ] } ] }